Interim results to 30 June showed encouraging progress, in the US in particular. An adjusted net loss of £10.3m (vs. -£6.1m) on the back of £2.0m revenues (vs. £0.5m) reflected the increase in US sales and marketing costs. However, key metrics to illustrate the ramp up in Accrufer sales, albeit from low levels (+350% increase in prescriptions written compared to H2 2022; a broadening of new prescribers and introductions to healthcare providers and a 350% increase in net selling price), indicate ....
08 Sep 2022
Shield Therapeutics - Interims – evidence of building momentum in US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Interims – evidence of building momentum in US
Shield Therapeutics Plc (STX:LON) | 1.3 0 (-7.0%) | Mkt Cap: 10.4m
- Published:
08 Sep 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
Interim results to 30 June showed encouraging progress, in the US in particular. An adjusted net loss of £10.3m (vs. -£6.1m) on the back of £2.0m revenues (vs. £0.5m) reflected the increase in US sales and marketing costs. However, key metrics to illustrate the ramp up in Accrufer sales, albeit from low levels (+350% increase in prescriptions written compared to H2 2022; a broadening of new prescribers and introductions to healthcare providers and a 350% increase in net selling price), indicate ....